Fluorescent primuline derivatives inhibit hepatitis C virus NS3-catalyzed RNA unwinding, peptide hydrolysis and viral replicase formation

Antiviral Research

Volumn 96, Issue 2, 2012, Pages 245-255

  Ndjomou, Jean ^a   Kolli, Rajesh ^a   Mukherjee, Sourav ^a   Shadrick, William R ^a   Hanson, Alicia M ^a   Sweeney, Noreena L ^a   Bartczak, Diana ^a   Li, Kelin ^b   Frankowski, Kevin J ^b   Schoenen, Frank J ^b   Frick, David N ^a  

^a UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

ATPase; Benzothiazole; Direct acting antiviral; Motor protein; Protease; RNA binding proteins

Indexed keywords

ADENOSINE TRIPHOSPHATE; BENZOTHIAZOLE DERIVATIVE; NONSTRUCTURAL PROTEIN 3; NUCLEIC ACID; PRIMULINE DERIVATIVE; RNA; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; CATALYSIS; CELL ACTIVITY; CONTROLLED STUDY; DENGUE VIRUS; DNA SYNTHESIS INHIBITION; DRUG SPECIFICITY; ENZYME SYNTHESIS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; DNA HELICASES; ENZYME INHIBITORS; FLUORESCENCE; HEPACIVIRUS; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; PROTEIN BINDING; RNA REPLICASE; SERINE ENDOPEPTIDASES; THIAZOLES; VIRAL NONSTRUCTURAL PROTEINS;

DENGUE VIRUS; HEPATITIS C VIRUS;

EID: 84867418390     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.08.006     Document Type: Article

References (44)

1. Angus A.G., Dalrymple D., Boulant S., McGivern D.R., Clayton R.F., Scott M.J., Adair R., Graham S., Owsianka A.M., Targett-Adams P., Li K., Wakita T., McLauchlan J., Lemon S.M., Patel A.H. Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. J. Gen. Virol. 2010, 91:122-132.
2. Bacon B.R., Gordon S.C., Lawitz E., Marcellin P., Vierling J.M., Zeuzem S., Poordad F., Goodman Z.D., Sings H.L., Boparai N., Burroughs M., Brass C.A., Albrecht J.K., Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 364:1207-1217.
3. Belon C.A., Frick D.N. Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C. Future Virol. 2009, 4:277-293.
4. Belon C.A., Frick D.N. Monitoring helicase activity with molecular beacons. BioTechniques 2008, 45:433-440. 442.
5. Belon C.A., High Y.D., Lin T.I., Pauwels F., Frick D.N. Mechanism and specificity of a symmetrical benzimidazolephenylcarboxamide helicase inhibitor. Biochemistry 2010, 49:1822-1832.
6. Beran R.K., Lindenbach B.D., Pyle A.M. The NS4A protein of hepatitis C virus promotes RNA-coupled ATP hydrolysis by the NS3 helicase. J. Virol. 2009, 83:3268-3275.
7. Beran R.K., Pyle A.M. Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase. J. Biol. Chem. 2008, 283:29929-29937.
8. Beran R.K., Serebrov V., Pyle A.M. The serine protease domain of hepatitis C viral NS3 activates RNA helicase activity by promoting the binding of RNA substrate. J. Biol. Chem. 2007, 282:34913-34920.
9. Ding S.C., Kohlway A.S., Pyle A.M. Unmasking the active helicase conformation of nonstructural protein 3 from hepatitis C virus. J. Virol. 2011, 85:4343-4353.
10. Enserink M. Infectious diseases. First specific drugs raise hopes for hepatitis C. Science 2011, 332:159-160.
11. Frick D.N. The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. Curr. Issues Mol. Biol. 2007, 9:1-20.
12. Frick D.N., Ginzburg O., Lam A.M. A method to simultaneously monitor hepatitis C virus NS3 helicase and protease activities. Methods Mol. Biol. 2010, 587:223-233.
13. Frick D.N., Rypma R.S., Lam A.M., Gu B. The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently. J. Biol. Chem. 2004, 279:1269-1280.
14. Garber K. Hepatitis C: move over interferon. Nat. Biotechnol. 2011, 29:963-966.
15. Gosert R., Egger D., Lohmann V., Bartenschlager R., Blum H.E., Bienz K., Moradpour D. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J. Virol. 2003, 77:5487-5492.
16. Graham R.K., Caiger P. Fluorescence staining for the determination of cell viability. Appl. Microbiol. 1969, 17:489-490.
17. Guntern R., Bouras C., Hof P.R., Vallet P.G. An improved thioflavine S method for staining neurofibrillary tangles and senile plaques in Alzheimer's disease. Experientia 1992, 48:8-10.
18. Hanson A.M., Hernandez J.J., Shadrick W.R., Frick D.N. Identification and analysis of inhibitors targeting the hepatitis C virus NS3 helicase. Methods Enzymol. 2012, 511:463-483.
19. Conn's Biological Stains: a Handbook of Dyes, Stains and Fluorochromes for Use in Biology and Medicine 2002, BIOS, Oxford, pp. 357-358. R.W. Horobin, J.A. Kiernan, H.J. Conn (Eds.).
20. Howe A.Y., Chase R., Taremi S.S., Risano C., Beyer B., Malcolm B., Lau J.Y. A novel recombinant single-chain hepatitis C virus NS3-NS4A protein with improved helicase activity. Protein Sci. 1999, 8:1332-1341.
21. Ivanyi-Nagy R., Kanevsky I., Gabus C., Lavergne J.P., Ficheux D., Penin F., Fosse P., Darlix J.L. Analysis of hepatitis C virus RNA dimerization and core-RNA interactions. Nucleic Acids Res. 2006, 34:2618-2633.
22. Jones C.T., Catanese M.T., Law L.M., Khetani S.R., Syder A.J., Ploss A., Oh T.S., Schoggins J.W., MacDonald M.R., Bhatia S.N., Rice C.M. Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat. Biotechnol. 2010, 28:167-171.
23. Lam A.M., Frick D.N. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J. Virol. 2006, 80:404-411.
24. Lam A.M., Keeney D., Eckert P.Q., Frick D.N. Hepatitis C virus NS3 ATPases/helicases from different genotypes exhibit variations in enzymatic properties. J. Virol. 2003, 77:3950-3961.
25. Lam A.M., Rypma R.S., Frick D.N. Enhanced nucleic acid binding to ATP-bound hepatitis C virus NS3 helicase at low pH activates RNA unwinding. Nucleic Acids Res. 2004, 32:4060-4070.
26. Lanzetta P.A., Alvarez L.J., Reinach P.S., Candia O.A. An improved assay for nanomole amounts of inorganic phosphate. Anal. Biochem. 1979, 100:95-97.
27. Levin M.K., Patel S.S. Helicase from hepatitis C virus, energetics of DNA binding. J. Biol. Chem. 2002, 277:29377-29385.
28. Li K., Frankowski K.J., Belon C.A., Neuenswander B., Ndjomou J., Hanson A.M., Shanahan M.A., Schoenen F.J., Blagg B.S., Aube J., Frick D.N. Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline. J. Med. Chem. 2012, 55:3319-3330.
29. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., Rice C.M. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
30. Lindenbach B.D., Pragai B.M., Montserret R., Beran R.K., Pyle A.M., Penin F., Rice C.M. The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication. J. Virol. 2007, 81:8905-8918.
31. Lindenbach B.D., Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436:933-938.
32. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113.
33. Luo D., Xu T., Watson R.P., Scherer-Becker D., Sampath A., Jahnke W., Yeong S.S., Wang C.H., Lim S.P., Strongin A., Vasudevan S.G., Lescar J. Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein. EMBO J. 2008, 27:3209-3219.
34. Mousseau G., Kota S., Takahashi V., Frick D.N., Strosberg A.D. Dimerization-driven interaction of hepatitis c virus core protein with NS3 helicase. J. Gen. Virol. 2011, 92:101-111.
35. Mukherjee, S., Hanson, A.M., Shadrick, W.R., Ndjomou, J., Sweeney, N.L., Hernandez, J.J., Bartczak, D., Li, K., Frankowski, K.J., Heck, J.A., Arnold, L.A., Schoenen, F.J., Frick, D.N., in press. Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays. Nucleic Acids Res, doi:10.1093/nar/gks623.
36. Murray C.L., Rice C.M. Turning hepatitis C into a real virus. Annu. Rev. Microbiol. 2011, 65:307-327.
37. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
38. Oshiumi H., Ikeda M., Matsumoto M., Watanabe A., Takeuchi O., Akira S., Kato N., Shimotohno K., Seya T. Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN-beta induction. PLoS One 2010, 5:e14258.
39. Preugschat F., Averett D.R., Clarke B.E., Porter D.J. A steady-state and pre-steady-state kinetic analysis of the NTPase activity associated with the hepatitis C virus NS3 helicase domain. J. Biol. Chem. 1996, 271:24449-24457.
40. Schiering N., D'Arcy A., Villard F., Simic O., Kamke M., Monnet G., Hassiepen U., Svergun D.I., Pulfer R., Eder J., Raman P., Bodendorf U. A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:21052-21056.
41. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11:791-796.
42. Xu T., Sampath A., Chao A., Wen D., Nanao M., Chene P., Vasudevan S.G., Lescar J. Structure of the dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4å. J. Virol. 2005, 79:10278-10288.
43. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., Focaccia R., Younossi Z., Foster G.R., Horban A., Ferenci P., Nevens F., Mullhaupt B., Pockros P., Terg R., Shouval D., van Hoek B., Weiland O., Van Heeswijk R., De Meyer S., Luo D., Boogaerts G., Polo R., Picchio G., Beumont M. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011, 364:2417-2428.
44. Zufferey R., Dull T., Mandel R.J., Bukovsky A., Quiroz D., Naldini L., Trono D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 1998, 72:9873-9880.